1.
Lorna Ewart, Adrian Roth. Opportunities and challenges with microphysiological systems: a pharma end-user perspective. Nature Reviews. Drug Discovery. 2021;20(5):327-328. doi:10.1038/d41573-020-00030-2
Drug Industry
1.
Uwe Marx, Takafumi Akabane, Tommy B. Andersson, et al. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 2020;37(3):365-394. doi:10.14573/altex.2001241
1.
S. Vincent Rajkumar. The high cost of prescription drugs: causes and solutions. Blood Cancer Journal. 2020;10(6):71. doi:10.1038/s41408-020-0338-x
1.
Jarrod Bailey, Michael Balls. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations. BMC Medical Ethics. 2019;20(1):16. doi:10.1186/s12910-019-0352-3
1.
Kathy Archibald, Katya Tsaioun, J. Gerry Kenna, Pandora Pound. Better science for safer medicines: the human imperative. Journal of the Royal Society of Medicine. 2018;111(12):433-438. doi:10.1177/0141076818812783
1.
Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012
1.
Matthew M. Davis, Amy T. Butchart, John R. C. Wheeler, Margaret S. Coleman, Dianne C. Singer, Gary L. Freed. Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine. 2011;29(51):9414-9416. doi:10.1016/j.vaccine.2011.09.128